Why You Don't Need to Cycle CJC-1295 or Tesamorelin

Your pituitary gland has two completely separate receptor systems that respond to growth hormone signals, and almost everything you read online treats them like one system because the peptides that target them often come packaged together.

That packaging mistake is where the confusion starts.

When you take CJC-1295 or tesamorelin together with ipamorelin, the standard advice is to run three months on and one month off. That cycling advice is real and correct, but the reason behind it only applies to half of what is in that vial. Understanding which half, and why, is what determines whether your off weeks are actually accomplishing anything.

To understand the problem, you need the full pathway first. Your hypothalamus releases something called GHRH, which stands for growth hormone releasing hormone, and it travels to your pituitary gland where it binds to GHRH receptors and tells the pituitary to release growth hormone into circulation. That growth hormone then travels to your liver and other tissues where it triggers the production of something called IGF-1, which is insulin-like growth factor 1, the downstream signal responsible for most of the tissue-level effects people are chasing. That is the chain. Hypothalamus signals pituitary, pituitary releases growth hormone, growth hormone drives IGF-1, IGF-1 does the work.

CJC-1295 and tesamorelin are both synthetic analogs of GHRH, meaning they work at that first receptor in the chain. Ipamorelin works through a completely different receptor called the ghrelin receptor, also on the pituitary, which produces a separate amplifying signal that layers on top of the GHRH signal. These two receptor systems operate independently, and that independence is not just theoretical. A 1991 study using perifused rat pituitary cells demonstrated directly that desensitizing the ghrelin receptor system had no effect on the GHRH receptor system and vice versa. They are separate switches.

Now here is where the cycling question actually lives. Receptors can do something called downregulation, which means the cell physically reduces the number of available receptors in response to being overstimulated, and it does this through a process called beta-arrestin mediated internalization, where the receptor gets pulled off the cell surface and tucked inside the cell so it can no longer respond to signals. When you continuously stimulate a receptor system without giving it time to reset, you end up with fewer receptors on the surface, and fewer receptors means a weaker response to the same dose.

For ipamorelin and ghrelin receptor agonists, this is a documented problem in humans. A 16-week trial tracking growth hormone response to continuous ghrelin receptor stimulation found that GH output declined approximately 45 percent from baseline by week 16. Not a small drift. Nearly half the response gone. When subjects stopped for four weeks, GH response came all the way back to starting levels. That recovery window is exactly what the three months on, one month off protocol is designed to preserve.

The ghrelin receptor is particularly susceptible to this because of dosing frequency. When you take ipamorelin multiple times per day, the receptor gets stimulated, partially recovers, gets stimulated again, and the window between doses is not long enough for full receptor repopulation on the cell surface.

Now compare that to what happens at the GHRH receptor when you take tesamorelin. Tesamorelin has a half-life of roughly 26 to 38 minutes in circulation. You inject it, it binds to GHRH receptors, delivers its signal, and then it is cleared. The receptors get a brief, clean pulse and then have more than 23 hours before the next dose arrives. That recovery window appears to be long enough that meaningful downregulation does not occur.

The clinical evidence supports this. In a 26-week randomized trial published in the New England Journal of Medicine, daily tesamorelin dosing produced sustained IGF-1 elevation throughout the entire study period with no attenuation of effect. When the FDA pooled Phase 3 data across the full 52-week period, IGF-1 levels and visceral fat reduction held steady through week 52 as well. There is no published human data showing GHRH receptor desensitization under a once-daily dosing schedule.

The same pattern holds with MK-677, which is a ghrelin mimetic, meaning it works through the same receptor system as ipamorelin. A two-year study in healthy older adults showed that GH and IGF-1 elevation was maintained across the full 24 months of continuous use. This seems to contradict what was said about ipamorelin, and the reason it does not is dosing frequency. MK-677 is taken orally once per day, which gives the ghrelin receptor a much longer recovery window than a peptide dosed two or three times daily. The receptor system is the same but the stimulation pattern is different, and that difference changes the desensitization outcome.

So if you are running CJC-1295 with ipamorelin and you cycle, you are cycling because of the ipamorelin, and the CJC is along for the ride. Stopping CJC during your off weeks is not doing anything for GHRH receptor recovery because there was no meaningful GHRH receptor desensitization to recover from.

If you are running tesamorelin alone at a once-daily dose, the published evidence does not support a requirement to cycle it. The receptor system it targets does not show the same internalization behavior under that dosing pattern, and the longest continuous-use data available shows sustained effect out to 52 weeks.

The practical takeaway is straightforward. If your protocol includes a ghrelin receptor agonist like ipamorelin, cycle it. Three months on, one month off is reasonable given the 45 percent decline and four-week recovery timeline from the human data. If your protocol is tesamorelin only, the cycling advice you see online is being borrowed from a desensitization concern that does not apply to the receptor system tesamorelin actually uses.

Most cycling advice is written for the receptor that has the problem and applied to everything in the vial. The two systems just happen to travel together.

---

References

1. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
3. FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
4. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
5. Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness